By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Ipsen 

39, rue du Bois Chaland

Evry Cedex    91029  France
Phone: 33-1-608-72600 Fax: 33-1-608-61609


SEARCH JOBS


Industry
Pharmaceutical






Company News
Ipsen (IPN.PA) Announces Publication In Pediatrics Of The Results Of The Phase III Randomized Study Showing The Efficacy And Safety Of Dysport(Abobotulinumtoxina) In Children With Dynamic Equinus Foot Deformity Due To Cerebral Palsy 1/27/2016 10:23:19 AM
Ipsen (IPN.PA) And Galderma Pharma S.A. Expand Current Distribution Agreement For Dysport In Aesthetic Indications To Some Key Asia-Pacific Territories1 1/6/2016 11:05:13 AM
Ipsen (IPN.PA) Announces Its Corporate Agenda For 2016 12/18/2015 3:31:46 PM
Ipsen (IPN.PA) And Interprotein Enter Into A Research Collaboration For Novel Peptides In Endocrinology 11/19/2015 11:40:21 AM
Ipsen (IPN.PA): Sales In The 3rd Quarter And First Nine Months Of 2015 10/29/2015 11:12:36 AM
Telesta (TSX:TST), Ipsen (IPN.PA) Strike $137 Million+ Bladder Cancer Pact 10/28/2015 6:06:19 AM
Ipsen (IPN.PA) And EpiVax, Inc. Collaborate To Produce Next Generation Botulinum Toxins 10/26/2015 12:41:22 PM
Ipsen (IPN.PA) And EpiVax, Inc. Collaborate To Produce Next Generation Botulinum Toxins 10/26/2015 12:21:24 PM
Ipsen (IPN.PA) Presents Additional Results From A Phase III Clinical Trial Of The Investigational Use Of Dysport® In Children With Spastic Equinus Foot Deformity Due To Cerebral Palsy 10/23/2015 10:36:58 AM
Ipsen (IPN.PA) Release: Presentation Of Results At The AACPDM Annual Meeting From A Phase III Trial Evaluating An Investigational Use Of Abobotulinumtoxina (Dysport) In Children With Spastic Equinus Foot Deformity Due To Cerebral Palsy 10/22/2015 11:38:37 AM
12345678910...
//-->